Skip to main content

Table 2 Characteristics of the selected studies evaluating resistin level with breast cancer in the meta-analysis

From: The first combined meta‐analytic approach for elucidating the relationship of circulating resistin levels and RETN gene polymorphisms with colorectal and breast cancer

Study ID

Country

Sample source

Sample type

Cases/controls

Assay type

Kit provider

Mean resistin level (ng/ml) ± SD

NOS score

Cases

Controls

Ahmed [40]

Iraq

Serum

Premenopausal

90/90

ELISA kit

Bio-Rad Laboratories

18.32 ± 2.4

3.5 ± 0.5

7

Alokail et al. [41]

KSA

Serum

Both

56/53

ELISA kit

Immunodiagnoztik

18.9 ± 1.2

15.2 ± 1

7

Aly et al. [42]

KSA

Serum

UD

35/40

ELISA kit

Invitrogen

4.42 ± 4.74

1.84 ± 2.35

7

Assiri & Kamel [43]

KSA

Serum

Postmenopausal

110/89

ELISA kit

R&D systems

26.24 ± 1.95

22.63 ± 3.99

8

Assiri et al. [44]

KSA

Serum

Both

82/68

ELISA kit

R&D systems

26.24 ± 1.59

22.69 ± 2.58

8

Crisóstomo et al. [45]

Portugal

Serum

Both

77/77

ELISA kit

Duo Set ELISA

14.58 ± 10

10.86 ± 8.55

8

Dalamaga et al. [46]

Greece

Serum

Postmenopausal

102/102

ELISA kit

Avibion

11.2 ± 6.4

7.7 ± 4.85

8

Dalamaga et al. [47]

Greece

Serum

Postmenopausal

103/103

ELISA kit

Avibion

11.24 ± 6.44

7.73 ± 4.85

8

Georgiou et al. [48]

Greece

Serum

Both

157/52

ELISA kit

BioVendor

6.09 ± 3.08

6.16 ± 1.85

7

Gunter et al. [49]

USA

Plasma

Postmenopausal

875/821

ELISA kit

EMD Millipore

12.1 ± 1.8

12.3 ± 1.933

8

Hou et al. [50]

China

Serum

Both

80/50

ELISA kit

R&D systems

26.35 ± 5.36

23.32 ± 4.75

7

Kang et al. [51]

Korea

Plasma

Both

41/43

ELISA kit

AdipoGen

5.23 ± 6.9

1.46 ± 2

8

Muñoz-Palomeque et al. [18]

Mexico

Serum

Postmenopausal

20/40

ELISA kit

Preprotech Kit

10.60 ± 2.08

8.26 ± 2.38

7

Patrício et al. [52]

Portugal

Serum

Both

64/52

ELISA kit

Duo Set ELISA

17.30 ± 12.6

11.60 ± 11.4

8

Wang et al. [53]

Taiwan

Serum

UD

240/100

ELISA kit

eBioscience

32.72 ± 13.42

27.36 ± 5.49

7

Total

   

2132/1780